Danicopan,eculizumab,ravulizumab
AstraZeneca
['alexion']
today at #eha2023, we presented phase iii results for our investigational, factor d inhibitor as an add-on to c5 inhibition for patients with #pnh experiencing clinically significant extravascular hemolysis. read more: 
Official Twitter feed of Alexion Pharmaceuticals in the U.S. Community guidelines: https://t.co/CDq4jNKuoe